急性移植物抗宿主病患者中的EASIX:一项回顾性队列分析
该回顾性分析在德国培训队列及德国和美国三个验证队列中,评估EASIX公式对异基因干细胞移植后急性GVHD患者总生存的预测价值。在清髓性预处理亚组中EASIX-GVHD未能预测总生存,而在降低强度预处理患者中EASIX-GVHD是总生存和非复发死亡的有力预测因素,并在两个成人降低强度预处理队列和一个以儿童为主的队列中验证成功。
要点
- 在降低强度预处理患者中,EASIX-GVHD对总生存和非复发死亡有强预测作用。
- 在清髓性预处理亚组中EASIX-GVHD未预测总生存,可能与GVHD发生时血小板减少有关。
- EASIX-GVHD可能成为未来制定风险适应性GVHD治疗策略的基础。
核心结论
- 在降低强度预处理患者中,EASIX-GVHD是GVHD后生存的有力预测因素。
- EASIX-GVHD可能成为未来制定风险适应性GVHD治疗策略的基础。
研究设计与样本
- 回顾性分析,包括一个培训队列(德国)和三个验证队列(德国和美国),共纳入311例接受连续异基因干细胞移植的急性GVHD患者。
- 主要终点为急性GVHD发生时测量的EASIX-GVHD对总生存的预测。
主要发现
- 在全部急性GVHD患者(n=311)中,EASIX-GVHD在单变量和多变量模型中预测总生存(单变量分析,每增加一倍的HR 1.16,95%CI 1.12-1.20,p=0.0004)。
- 在清髓性预处理亚组(n=72)中,EASIX-GVHD未预测总生存,可能归因于GVHD发生时的血小板减少(清髓性预处理组血小板73×10^9/L [IQR 29.75-180.00] vs 降低强度预处理组160×10^9/L [90.0-250.5],p<0.0001)。
- 在降低强度预处理患者(n=239)中,EASIX-GVHD是总生存的强预测因素(每变化两倍的HR 1.23,95%CI 1.13-1.34;p<0.0001)和非复发死亡的强预测因素(每变化两倍的原因特异性HR 1.24,95%CI 1.12-1.38;p<0.0001)。
- EASIX-GVHD对总生存和非复发死亡的模型验证在两个成人降低强度预处理独立队列(n=141,n=173)和一个以儿童为主的队列(n=89)中成功。
关键数值与推荐
- EASIX公式为乳酸脱氢酶(U/L)×肌酐(mg/dL)/血小板(10^9细胞/L)。
- 在降低强度预处理患者中,EASIX-GVHD每变化两倍的总生存HR为1.23(95%CI 1.13-1.34;p<0.0001)。
- 在降低强度预处理患者中,EASIX-GVHD每变化两倍的非复发死亡原因特异性HR为1.24(95%CI 1.12-1.38;p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endothelial dysfunction links thrombotic microangiopathy to steroid-refractory graft-versus-host disease (GVHD) after allogeneic stem-cell transplantation. We aimed to assess if the simple formula-lactate dehydrogenase (U/L) × creatinine (mg/dL)/thrombocytes (109 cells per L)-termed the Endothelial Activation and Stress Index (EASIX), might be valuable for the prediction of death in patients with acute GVHD after allogeneic stem-cell transplantation. METHODS: For this retrospective analysis, we analysed a training cohort (in Germany) and three validation cohorts (in Germany and the USA) of patients with acute GVHD who had received consecutive allogeneic stem-cell transplantation. The primary endpoint was prediction of overall survival when measured at acute GVHD onset (EASIX-GVHD). We validated the prognostic strength of EASIX-GVHD for overall survival and non-relapse mortality in the three independent cohorts by calculating the prediction error (integrated Brier score), and concordance index. FINDINGS: In the total cohort of patients with acute GVHD (n=311), EASIX-GVHD predicted overall survival in univariable and multivariable models (univariate analysis, hazard ratio [HR] for a one-fold increase 1·16, 95% CI 1·12-1·20, p=0·0004). However, in the subpopulation of patients with myeloablative conditioning (n=72), EASIX-GVHD did not predict overall survival, which is probably attributable to thrombocytopenia at GVHD onset (73 × 109 cells per L [IQR 29·75-180·00] for myeloablative conditioning vs 160 × 109 cells per L [90·0-250·5] for reduced-intensity conditioning; p<0·0001). In patients who received reduced-intensity conditioning (n=239), EASIX-GVHD was a strong predictor of overall survival (HR for a two-fold change of 1·23, 95% CI 1·13-1·34; p<0·0001) and non-relapse mortality (cause-specific HR for a two-fold change of 1·24, 1·12-1·38; p<0·0001). Model validation for prediction of overall survival and non-relapse mortality by EASIX-GVHD was successful in two independent cohorts of adult patients with reduced-intensity conditioning (n=141, n=173) and in a cohort with mainly paediatric patients (n=89). INTERPRETATION: In patients with reduced-intensity conditioning, EASIX-GVHD is a powerful predictor of survival after GVHD. EASIX-GVHD could be the future basis for development of risk-adapted GVHD treatment strategies. FUNDING: There was no external funding source for this study.
引用
- Luft T, Benner A, Jodele S, et al. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol. 2017. PMID: 28733186. doi:10.1016/S2352-3026(17)30108-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。